Sarepta Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 4 Sell calls were followed by roughly flat moves (-1%) three months out.
- Recent price momentum is -24.9% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 18.3% of float.
- Analyst tilt is Hold.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 61.8% | Better than 76% |
| Operating margin | -29.9% | Better than 11% |
| Net margin | -32.5% | Better than 10% |
| Return on equity | -53.5% | Better than 9% |
| Return on invested capital | -28.2% | Better than 11% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -29.1% | Better than 19% |
| 6-month return | -20.7% | Better than 26% |
| 12-month return (ex latest month) | 2.8% | Better than 37% |
| Distance below 52-week high | 46.0% | Better than 22% |
Financial Health C-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.3x | Better than 63% |
| Debt to assets | 31.0% | Better than 40% |
| Interest coverage | -17.4x | Better than 10% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 20.0% | Better than 9% |
| Upside to average target | 67.5% | Better than 75% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 14.17
- Open
- 13.92
- Day range
- 13.25 - 14.47
- Avg price
- 13.67
- Volume
- 2.25M
- Turnover
- 30.80M
- Turnover ratei
- 2.21%
- Volume ratioi
- 1.16
- Amplitudei
- 8.58%
- 52-week rangei
- 13.25 - 24.68
Valuation
- P/Ei
- -1.87
- P/E (TTM)i
- -10.33
- P/Bi
- 0.93
- EPSi
- -7.13
- Book value / shi
- 14.26
- Net profit
- -764.59M
- Net assets
- 1.53B
Share structure
- Market cap
- 1.43B
- Float capi
- 1.36B
- Shares out
- 107.24M
- Float sharesi
- 102.15M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
46.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-7.47M net over the window
Short interest
- Shares short
- 19.30M
- % of floati
- 18.27%
- Days to coveri
- 7.82
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Sarepta Therapeutics (SRPT)?
Sarepta Therapeutics last traded at 13.33. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Sarepta Therapeutics's market cap?
About 1.43B.
What is the P/E ratio of Sarepta Therapeutics?
The trailing twelve-month P/E is -10.33, below its own 5-year average of 23.56 — in the middle of its historical range (42.58% percentile). See the Valuation tab for the full history.
Does Sarepta Therapeutics pay a dividend?
Sarepta Therapeutics does not currently pay a regular dividend.
Is Sarepta Therapeutics a buy according to analysts?
The consensus of 15 analysts is a Hold rating, with an average 12-month price target of 22.33, which implies 67.5% upside from the current price. This is not investment advice.
What is Sarepta Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Sarepta Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:54:28 · For reference only, not investment advice and not tailored to your situation.
Sarepta Therapeutics discussion 0 comments